#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Herpes simplex Sickle cell anaemia Pouchitis Squamous cell carcinoma of head and neck Myxoid liposarcoma Ocular myasthenia Vulval cancer Hyperphagia Congenital absence of bile ducts Ventricular fibrillation B-cell small lymphocytic lymphoma recurrent Deafness bilateral Short stature homeobox gene mutation Ewing's sarcoma metastatic Monogenic diabetes More trials…

    Learn about Rare Diseases

    Gastrointestinal stromal tumour – Basic Information Alexander disease – Diagnostics Atypical haemolytic uraemic syndrome – Trials in Disease Lysosomal storage disorder – Diagnostics Congenital hypotransferrinaemia – Trials in Disease Rosai-Dorfman syndrome Mantle cell lymphoma stage II – Life with Disease Thrombotic thrombocytopenic purpura – Basic Information Synovial sarcoma – Life with Disease Haemophagocytic lymphohistiocytosis More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Levonorgestrel Autologous Pancreatic Islets Adapalene Fenoterol Hydrobromide Citalopram Deflazacort Exenatide Dexamethasone Sodium Phosphate Bay 2927088 Tremelimumab Pegunigalsidase Alfa (-)-PHENSERINE TARTRATE Etuvetidigene Autotemcel Solrikitug Efepoetin Alfa BGB-16673 Sodium Cromoglicate Calcifediol Belzupacap Sarotalocan Ciltacabtagene Autoleucel More therapies…

    Learn about Your Condition

    Obstructive pancreatitis Follicular lymphoma stage IV Corneal graft rejection Sexual dysfunction Chorioretinitis Neuropathic arthropathy Morning sickness Hysterectomy Periodontitis Diverticulitis Hypoglycaemia Alcohol abuse Lumbosacral radiculopathy Retinopathy of prematurity Papulopustular rosacea More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Istituto Oncologico Veneto

Istituto Oncologico Veneto

Via Gattamelata 64, Padua, 35128, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effectiveness and Safety of Osimertinib for Patients with Stage IB-IIIA Non-Small Cell Lung Cancer After Tumor Removal

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    • Non-small cell lung cancer stage I
    • Non-small cell lung cancer stage II
    Investigated Drugs:
    • Osimertinib
    Belgium France Germany Italy Poland Spain +1

  • Study on Retreatment with Encorafenib and Cetuximab for Patients with BRAF V600E Mutated Metastatic Colorectal Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Cetuximab
    • Encorafenib
    Italy

  • Study on Melanoma Treatment: Comparing Encorafenib and Binimetinib with Ipilimumab and Nivolumab for Patients with BRAF V600 Mutation

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Binimetinib
    • Encorafenib
    • Ipilimumab
    France Germany Italy The Netherlands Poland Spain

  • Study of Entrectinib for Patients with Advanced or Metastatic Solid Tumors with Specific Gene Changes

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    • Neoplasm malignant
    Investigated Drugs:
    • Entrectinib
    France Germany Italy The Netherlands Poland Spain

  • Study on Vimseltinib for Patients with Tenosynovial Giant Cell Tumor

    Not recruiting

    3 1
    Investigated Drugs:
    • Vimseltinib
    France Germany Italy The Netherlands Norway Poland +1

  • Study of Pembrolizumab for Patients with Early Stage Non-Small Cell Lung Cancer After Surgery and Standard Therapy

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Pembrolizumab
    Austria Belgium Czechia Denmark Estonia France +11

  • Study of Lurbinectedin Alone or with Irinotecan for Patients with Relapsed Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Small cell lung cancer
    Investigated Drugs:
    • Irinotecan
    • Lurbinectedin
    • Topotecan
    Austria Belgium Bulgaria Denmark France Germany +5

  • Study on the Effectiveness of Decitabine and Venetoclax for Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia (in remission)
    Investigated Drugs:
    • Decitabine
    • Venetoclax
    Italy

  • Study of Tepotinib and Osimertinib for Patients with Advanced or Metastatic Lung Cancer Resistant to Osimertinib Therapy

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Osimertinib
    • Tepotinib
    Belgium France Germany Italy Spain

  • Comparison of Nilotinib versus Imatinib treatment in newly diagnosed chronic myeloid leukemia patients to achieve treatment-free remission

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Imatinib
    • Nilotinib
    Italy The Netherlands
Previous Page
1 … 34 35 36 37 38 … 42
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!